CoChat

The age factor in Alzheimer’s disease

Open access
Guerreiro, Rita, Bras, Jose · 2015 · Genome Medicine

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease is the most common type of dementia, and it is characterized by a decline in memory or other thinking skills.The greatest risk factor for Alzheimer's disease is advanced age.A recent genome-wide study identified a locus on chromosome 17 associated with the age at onset, and a specific variant in CCL11 is probably responsible for the association.The association of a protective haplotype with a 10-year delay in the onset of Alzheimer's disease and the identification of a CCL11 variant with possible functional roles in this association might allow the future development of immunomodulators with the potential to halve disease incidence.Alzheimer's disease (AD) is a common and multifactorial neurodegenerative disease.It is one of the leading causes of death around the world and is associated with substantial direct and indirect costs for families and societies.The vast majority of AD cases have a late onset (usually after 65 years of age); the disease is rare among younger individuals.Incidence of AD is known to increase with age, and age is the most important risk factor for the development of AD.The ability to delay the age at onset (AAO) of this disease through preventive or therapeutic approaches would have significant benefits, but no therapies have been successful in achieving this important goal [1,2].A recent study by Lalli et al.[3] used genome-wide technologies to identify genetic modifiers of AAO in a unique cohort comprising an extended Colombian family carrying the PSEN1 p.E280A mutation, and the outcome might be useful for guiding the search for therapies.Age at onset as a highly heritable factor in AD AAO is highly heritable in AD families.In early-onset cases, mutations in three genes are known to account

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-015-0232-5

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 416

Metadata

Authors
Guerreiro, R., & Bras, J.
Affiliations
UCL Queen Square Institute of Neurology (GB)
Corresponding author
Guerreiro, Rita
Venue
Genome Medicine
Published
2015-10-20
Volume
7
Issue
1
Pages
106-106
ISSN
1756-994X (ISSN-L)
OpenAlex
W1761228750
Cited by
415
References
13
Citations by year
2026: 30 · 2025: 48 · 2024: 68 · 2023: 60 · 2022: 65 · 2021: 53 · 2020: 42 · 2019: 33 · 2018: 12 · 2017: 3 · 2016: 1
FWCI
3.93
Type
journal article
Language
en
Open access
Locations
  • Genome Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Alzheimer's Society
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, age of onset, late-onset Alzheimer's disease, age as risk factor, eotaxin, genetic modifiers, PSEN1 E280A mutation, heritability, protective haplotypes, immunomodulators
MeSH terms
Age Factors, Alzheimer Disease, Animals, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The age factor in Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13073-015-0232-5
The paper
Guerreiro, R., & Bras, J. (2015). The age factor in Alzheimer’s disease. Genome Medicine. https://doi.org/10.1186/s13073-015-0232-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.